Maze Therapeutics, Inc. (MAZE) — Stock Score Summary

Maze Therapeutics, Inc. (MAZE) has a MoatMap StockRank of 5/100 based on Quality (33/100), Value (35/100), and Momentum (15/100) factor scores. The current signal is STRONG SELL. Fails to meet the fund's strict quality and macro alignment criteria. The combination of a strong quant sell signal, lack of clear competitive moat, and absence of high-conviction macro tailwinds makes this an easy pass.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary "human genetic discovery engine" to identify and validate novel drug targets for common diseases. By integrating human genetics and functional genomics, the company aims to develop precision medicines that modulate disease-modifying genes. Its competitive advantage lies in its unique platform for identifying genetically-driven therapeutic opportunities and its focus on developing highly targeted treatments for underserved patient populations.

Key Financial Metrics

Price$23.93
Market Cap$1.5B
P/E (Forward)-7.68
Price/Book3.67
Return on Equity-38.7%
Return on Invested Capital-38.2%
Debt/Equity17.92
Gross Margin100.0%
Operating Margin-132.8%
Free Cash Flow$-82M

Maze Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Maze Therapeutics, Inc.’s (MAZE) StockRank?
MoatMap’s StockRank for Maze Therapeutics, Inc. (MAZE) is 5/100, with a Strong Sell signal. It is a composite of Quality (33), Value (35), and Momentum (15) factor ranks across MoatMap’s 19,000+ stock universe.
Does Maze Therapeutics, Inc. have an economic moat?
Maze Therapeutics, Inc. (MAZE) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Maze Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Maze Therapeutics, Inc. (MAZE) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. (MAZE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksMAZE deep dive reportAI ChampionsHow we score stocksSense-check another stock